Share

Are Golden Tickets That Speed Drugs Through FDA Worthwhile?

Sarepta Therapeutics was awarded a document for a fast-track drug examination by a Food and Drug Administration when a company’s medicine for Duchenne robust dystropy was certified Sept. 19. Now Sarepta is looking to sell a document to a tip bidder.

Mick Wiggins/Ikon Images/Getty Images


hide caption

toggle caption

Mick Wiggins/Ikon Images/Getty Images

Sarepta Therapeutics was awarded a document for a fast-track drug examination by a Food and Drug Administration when a company’s medicine for Duchenne robust dystropy was certified Sept. 19. Now Sarepta is looking to sell a document to a tip bidder.

Mick Wiggins/Ikon Images/Getty Images

Drugmaker Sarepta Therapeutics won a large feat when a $300,000 robust dystrophy drug was certified Sept. 19, notwithstanding questions about a effectiveness.

But a association had other reasons to celebrate. It was also awarded a curative industry’s chronicle of a Willy Wonka golden ticket.

The ticket, famous as a priority examination voucher, was combined by Congress in 2007 to inspire a growth of drugs for neglected pleasant diseases and was stretched in 2012 to singular pediatric disorders. A association that gets a subordinate drug certified can be awarded a document that can be redeemed for a fast-track supervision examination of one of a destiny drugs. Or a document hilt can sell a golden sheet to a tip bidder.

A document can assistance a drug association leapfrog a rival.

Controversy Continues Over Muscular Dystrophy Drug, Despite FDA Approval

“The usually people who would buy a priority examination document would be someone who had something that wouldn’t consequence a possess priority examination though they wish a priority review,” says Dr. Tim Coté, a former FDA central who now runs a consulting organisation for singular illness drugs.

A document guarantees a association that a drug will be reviewed within 6 months, as compared with a customary 10. But capitulation isn’t assured, only a speedier decision.

The sale of a document can acquire a lot of income for a tiny association like Sarepta. Last year, a document sole for a record $350 million when AbbVie Inc. bought one from United Therapeutics. AbbVie hasn’t disclosed a skeleton for a voucher.

Members of Congress, a curative attention and rare-disease advocates have sexually upheld vouchers as a approach to coax growth of drugs for singular and neglected diseases. But skeptics, including FDA officials and some academics, have questioned either a module is profitable off.

Nancy Goodman, executive executive of Kids v Cancer, is a champion of vouchers. She combined her substructure after her son died 7 years ago of medulloblastoma, a form of mind cancer that mostly affects children.

There were no drugs accessible for her 10-year-old son, she said. “I trust and wish we will see a whole stand of pediatric illness drugs since of a program,” Goodman said.

Legislation fluctuating a pediatric document module by early Dec upheld a House and Senate by unanimous agree and awaits movement by President Obama, who is approaching to pointer it. The module was set to end Oct. 1.

Advocates are fighting to keep a module certified until Dec. 21, 2018, as partial of a 21st Century Cures Act, that has upheld a House and has stalled in a Senate, where backers wish it will be taken adult after a elections.

But officials during a FDA, that contingency exercise a vouchers, are during contingency with attention and advocates.

Dr. John Jenkins, executive of a bureau of new drugs in a Center for Drug Evaluation and Research during a FDA, has pronounced he supports a altogether idea of providing incentives to foster drug growth though that a document module is wrong.

In December, Jenkins told a attention announcement Pharmaceutical Executive that vouchers lift reserve concerns since a module requires a FDA to give any drug accelerated examination – even when reviewers have to residence formidable issues. “We’re not creation pizza here,” he said.

Jenkins declined talk requests for this story. FDA mouthpiece Sandy Walsh said, a “FDA has not seen justification that a module is effective.”

Walsh also pronounced a group is endangered that a document module “adversely affects a agency’s ability to set a open health priorities” and “the additional effort from a module strains a agency’s resources.”

The document module does need companies to compensate an additional user price of scarcely $3 million on tip of a customary price to examination a drug, in sequence to assistance a group compensate for a program.

Price Rises For Ticket To A Quicker Drug Review By FDA

But a additional income might not be sufficient.

In March, a Government Accountability Office news on pediatric vouchers pronounced FDA officials protest there is too small time to use a income to sinecure and sight additional employees to do accelerated reviews and that a one-time price does not capacitate employing of long-term staff.

The GAO’s news pronounced it was too early to contend either a module is sensitive growth of drugs for singular childhood disease. Of a 7 pediatric examination vouchers that have been awarded, 4 have been sole to other drug companies.

Drugmaker Sanofi has redeemed dual pediatric vouchers. For a first, it paid $67.5 million to BioMarin, developer of a diagnosis for Morquio A syndrome, a rare, hereditary disorder, and used it to assist examination of a cholesterol drug Praluent. Later, Sanofi spent $245 million for a pediatric document from Asklepion Pharmaceuticals, builder of diagnosis for a singular childhood metabolic disease. Sanofi pronounced in Feb it would be used to speed adult a FDA’s preference on a Type 2 diabetes treatment.

Vouchers don’t expire. If a document isn’t used, it can be sole an total series of times.

Sarepta skeleton to sell a voucher. Chief Financial Officer Sandy Mahatme told Wall Street analysts a association has already reached out to “a garland of intensity buyers.” He pronounced a deduction would assistance financial other drugs in a pipeline, compensate to scale adult a production ability and support a company’s entrance into European markets.

Kaiser Health News is an editorially eccentric news use upheld by a inactive Kaiser Family Foundation. Follow Sarah Jane Tribble on Twitter: @sjtribble.